Vice President
Annexon Biosciences
Vice President
Annexon Biosciences
Develops C1q inhibitor therapies
Company:
At Annexon Biosciences we are a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Our novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, we are rigorously advancing our mid-to late-stage clinical trials to bring new potential treatments to patients as quickly as possible. At Annexon, you’ll be part of a team committed to making an impact together.
For more information on Annexon and our pipeline, check out our site Annexon Biosciences & Annexon Pipeline. We trade on Nasdaq under the ticker symbol ANNX and are headquartered in Brisbane, CA.
We're seeking exceptional talent from all backgrounds to fuel our growth. At Annexon, we're building a diverse, equitable, and inclusive workplace. We value unique perspectives and unconventional paths. If you're the best candidate for the job, even if you don't perfectly fit the traditional mold, we encourage you to apply. Learn more about our commitment to diversity, equity, inclusion, and our company culture!
Work Location: Corporate Headquarters (South San Francisco / Brisbane, CA) Onsite – Hybrid Non-local candidates will be considered
Position:
We are seeking an accomplished, experienced, and creative development leader to join our team as Vice President, Translational Medicine. The VP, Translational Medicine will play a critical role in shaping and executing Annexon’s translational strategy across our portfolio of classical complement biology programs spanning diseases of the body, brain, and eye.
This position will serve as a key scientific and strategic partner to Clinical Development, Discovery, Regulatory, Clinical Operations, and Medical Affairs—ensuring that mechanistic hypotheses are translated into human biology evidence, biomarker strategies, and data-driven decision-making to accelerate development. The VP, Translational Medicine will lead translational planning and execution for flagship and next-wave programs, including tanruprubart (ANX005) in Guillain-Barré syndrome (GBS), vonaprument (ANX007) in dry AMD with geographic atrophy (GA), neurodegenerative programs including Huntington’s disease and ALS.
This role requires a seasoned leader with deep expertise in translational medicine, biomarker strategy, assay development, bioinformatics, statistics, artificial intelligence/machine learning, and clinical development— and a track record of building and leading high-performing translational organizations within pharma or biopharma. Like all Annexon leaders, the VP, Translational Medicine incumbent will have a deep-rooted commitment to serving patients and a passion for transforming the lives of people with serious diseases and their families.
Responsibilities include:
Education, Experience, and Skills:
Qualifications:
Location: Annexon Biosciences is located in Brisbane, California and preference is given to candidates in the San Francisco Bay Area.
Salary Range: $310,000 – $340,000
Benefits:
Annexon Biosciences is an Equal Opportunity Employer, and we prohibit discrimination or harassment of any kind. We are committed to fostering an environment where ALL people are welcome and supported. We cultivate a culture of inclusion for all employees that respects their individual strengths, views, and experiences. We believe that our differences enable us to be a better team – one that makes better decisions, drives innovation, and delivers better business results. Creativity and innovation flourish in an environment of openness, inclusion, and mutual respect.
Develops C1q inhibitor therapies
Annexon Biosciences develops therapies that target the classical complement pathway to treat autoimmune and neurodegenerative diseases, including eye conditions. Its main strategy is to inhibit C1q, the molecule that starts the complement cascade, with the aim of stopping disease progression at its source. The company advances therapies through clinical trials and may either commercialize them or partner with larger pharma firms to bring them to market. Revenue potential comes from product sales, licensing, and milestone payments from collaborations. Annexon’s goal is to deliver first-in-class C1q inhibitors that prevent tissue damage across diseases such as Alzheimer's, Huntington's, glaucoma, and related disorders, supported by substantial financing to push its pipeline forward.
Explore more opportunities at Annexon Biosciences